Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -146.09M | -133.81M | -124.29M | -115.88M | -105.85M |
| Total Depreciation and Amortization | 2.32M | 2.29M | 2.19M | 2.09M | 2.02M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.58M | 12.17M | 10.01M | 8.56M | 8.00M |
| Change in Net Operating Assets | 7.89M | 10.33M | 3.19M | 1.65M | -1.89M |
| Cash from Operations | -118.30M | -109.03M | -108.90M | -103.59M | -97.72M |
| Capital Expenditure | -1.06M | -1.31M | -1.20M | -1.14M | -1.67M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 128.61M | -183.34M | -177.40M | -179.40M | -212.79M |
| Cash from Investing | 127.55M | -184.66M | -178.60M | -180.54M | -214.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.70M | 249.52M | 299.56M | 296.01M | 294.38M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -300.00K | -262.00K | -213.00K | -213.00K | -165.00K |
| Cash from Financing | 10.40M | 249.25M | 299.35M | 295.80M | 294.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.66M | -44.43M | 11.85M | 11.68M | -17.97M |